Diabetic neuropathy (DN) is one of the most common complications of diabetes, and has a prevalence of as high as 50% in diabetic patients. Allodynia and hyperalgesia are early symptoms of the disease. Sensory paralysis is a late symptom, and is frequently accompanied by a poor prognosis, including limb amputation. However, there is currently no effective treatment for DN. In the present study, we evaluated the effect of a bioactive natural product in a mouse model of DN produced by injection of 200 mg/kg streptozotocin (STZ). The bioactive natural product, 30 mg/kg, was administered to the diabetic mice for a period of 3 weeks, starting 1 week after the STZ injection. The behavioral effects of the bioactive natural product were evaluated using the von Frey test (to assess mechanical allodynia) and the hot plate test (to assess thermal hyperalgesia). Furthermore, we examined conduction velocity and blood flow in the sciatic nerve. Treatment with the bioactive natural product ameliorated the allodynia and hyperalgesia, and it increased conduction velocity and blood flow in the sciatic nerve in the diabetic mice with DN. These findings suggest that the bioactive natural product has therapeutic potential for the treatment of DN.